Analysts Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Target Price at $15.88

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $17.00.

A number of brokerages have issued reports on TEVA. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 20th. Piper Sandler reissued an “overweight” rating and set a $20.00 price target (up from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Barclays upped their price target on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, June 5th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target on the stock in a research report on Friday, March 8th. Finally, Jefferies Financial Group upped their price target on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 519,000 shares of the stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the transaction, the director now owns 981,000 shares of the company’s stock, valued at $16,706,430. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CAO Amir Weiss sold 15,500 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $16.80, for a total transaction of $260,400.00. Following the completion of the transaction, the chief accounting officer now owns 17,814 shares of the company’s stock, valued at $299,275.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at approximately $16,706,430. The disclosure for this sale can be found here. Over the last quarter, insiders sold 549,719 shares of company stock valued at $9,353,736. 0.55% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TEVA. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $30,000. Industrial Alliance Investment Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $54,000. Blue Trust Inc. boosted its position in shares of Teva Pharmaceutical Industries by 92.3% in the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after purchasing an additional 2,180 shares during the period. Finally, Psagot Value Holdings Ltd. Israel acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $57,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.1 %

NYSE TEVA opened at $16.25 on Thursday. The stock has a market cap of $18.41 billion, a PE ratio of -39.63, a P/E/G ratio of 1.54 and a beta of 0.91. Teva Pharmaceutical Industries has a fifty-two week low of $7.42 and a fifty-two week high of $17.69. The business has a 50 day moving average price of $15.99 and a two-hundred day moving average price of $13.68. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The company had revenue of $3.82 billion during the quarter, compared to analysts’ expectations of $3.70 billion. Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. As a group, sell-side analysts predict that Teva Pharmaceutical Industries will post 2.32 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.